Physician profile

Jennifer Ott

Medical · Dothan, AL

NPI 1780780759

$193.74

in general payments reported to CMS, 2019-2025

2 companies · $72.32 in 2025

The $72.32 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$193.74

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Tempus Ai, INC $121.42 2024
Astrazeneca Pharmaceuticals LP $72.32 2025 Breztri, Airsupra

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jennifer Ott

$193.74

in general payments reported 2019-2025

Years
2024-2025
Top company
Tempus Ai, INC
Context
The $72.32 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).

https://glasscript.com/doctor/10489727/jennifer-ott

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.